You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
綠葉製藥(02186.HK):羅替高汀貼片Rotigotine Luye在英國上市
格隆匯 04-10 18:10

綠葉製藥(02186.HK)公吿,集團開發的羅替高汀貼片Rotigotine Luye已於近期在英國上市,用於治療早期和晚期特發性帕金森病的體徵和症狀,以及用於治療中重度特發性不寧腿綜合徵。該產品是首款在英國上市的Neupro®的仿製藥,與Neupro®具有生物等效性。

Rotigotine Luye與Neupro®具有相同的劑量規格,在保持同等釋藥劑量的情況下,Rotigotine Luye具有更低的載藥量,貼片大小相較Neupro®小8%。此外,Rotigotine Luye的粘附基質層不含焦亞硫酸鈉。焦亞硫酸鈉是一種已知可能引發過敏反應的接觸性過敏原。

帕金森病是全球第二大常見的神經退行性疾病,患者人數超過1,000萬人。該疾病會導致患者行動不便以及心理健康、睡眠、疼痛和其他健康問題,其症狀隨時間的推移而惡化,嚴重影響患者的身心健康和生活質量。不寧腿綜合徵則是一種常見的神經感覺障礙,影響全球約3%的人口。該疾病會導致患者出現幾乎不可抗拒的活動腿的慾望,症狀嚴重時可顯著干擾患者的日常活動。羅替高汀作為一種多巴胺受體激動劑,可改善帕金森病患者的運動症狀和非運動症狀,並可有效緩解不寧腿綜合徵患者的症狀。

Rotigotine Luye是集團在英國上市的第六款中樞神經系統治療領域產品。在英國市場以外,Rotigotine Luye也已在德國上市。公司計劃攜手合作夥伴面向全球更多國家推出該產品。Rotigotine Luye由集團在德國的生產基地生產。該生產基地專注於透皮釋藥技術逾20年,是當前歐洲最大的獨立透皮系統製造商一。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account